Syngene International (BOM:539268) Cash And Cash Equivalents : ₹857 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Syngene International Cash And Cash Equivalents?

Syngene International's quarterly cash and cash equivalents declined from Sep. 2023 (₹1,683.00 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹857.00 Mil).

Syngene International's annual cash and cash equivalents declined from Mar. 2022 (₹2,610.00 Mil) to Mar. 2023 (₹870.00 Mil) and declined from Mar. 2023 (₹870.00 Mil) to Mar. 2024 (₹857.00 Mil).

Syngene International Cash And Cash Equivalents Historical Data

The historical data trend for Syngene International's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syngene International Cash And Cash Equivalents Chart

Syngene International Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,922.00

3,220.00

2,610.00

870.00

857.00

Syngene International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															870.00	-	1,683.00	-	857.00

Syngene International Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Syngene International (BOM:539268) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Syngene International Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Syngene International's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Syngene International (BOM:539268) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syngene International Ltd (BOM:539268) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SYNGENE:India

Address

Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099

Website

https://www.syngeneintl.com

Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.

Syngene International (BOM:539268) Headlines

No Headlines